TRACY HICKS: Open Payments
NPI 1215353651 · LONGVIEW, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$269,985 in 445 payments from 14 companies in 2025. Trend: 2023 $102,500 · 2024 $200,299 · 2025 $269,985
Speaker / faculty: $187,774Consulting: $42,645Travel & lodging: $29,182Food & beverage: $10,384
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 170 | $128,675 |
| Neurocrine BioSciences, Inc. | 106 | $64,297 |
| Teva Pharmaceuticals USA, Inc. | 73 | $48,482 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 29 | $19,904 |
| Alkermes, Inc. | 26 | $7,823 |
| Vanda Pharmaceuticals Inc. | 10 | $218 |
| ABBVIE INC. | 13 | $135 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $126 |
| Otsuka America Pharmaceutical, Inc. | 6 | $114 |
| Indivior Inc. | 4 | $74 |
Products named: COBENFY, INGREZZA, UZEDY, CAPLYTA, AUSTEDO XR, LYBALVI, ARISTADA, FANAPT.
Industry payments across TX — which companies pay providers there.
